Azithromycin ophthalmic - Senju Pharmaceutical

Drug Profile

Azithromycin ophthalmic - Senju Pharmaceutical

Alternative Names: SJP-0118

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senju Pharmaceutical
  • Developer Senju Pharmaceutical; Tottori University Hospital
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Infectious conjunctivitis
  • No development reported Blepharitis; Ocular inflammation

Most Recent Events

  • 13 Jun 2018 Azithromycin is still in phase III trials for Infectious conjunctivitis in Japan (Senju Pharmaceutical pipeline, June 2018)
  • 13 Jun 2018 No recent reports on development identified - Phase-III for Blepharitis in Japan (Instillation)
  • 13 Jun 2018 No recent reports on development identified - Phase-III for Ocular inflammation in Japan (Instillation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top